Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 23 November 2023, 09:15 HKT/SGT
Share:
    

Source: OrbusNeich Medical Group Holdings Limited
OrbusNeich Adds Drug-eluting Balloons in Product Portfolio Through Acquisition of Eucatech AG

HONG KONG, Nov 23, 2023 - (ACN Newswire) - OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today announced the acquisition of 100% interest in Eucatech AG, a German company principally engaged in the development, manufacture, and sale of minimally invasive cardiovascular and endovascular projects, for EUR2,400,000. Upon completion of the acquisition, Eucatech AG will become a wholly-owned subsidiary of the Group.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, "We are pleased to announce the acquisition of Eucatech AG, a company with two decades of experience and a shared mission with OrbusNeich. We believe that this acquisition will enrich our product portfolio. In particular, its CE marked products, including coronary stent with sirolimus coating, peripheral self-expandable stent and paclitaxel-coated PTCA and PTA balloons will enhance our ability to treat lesions in PCI and PTA procedures. In addition, by leveraging our strong sales network, these cutting-edge products are expected to drive growth and further fulfill our commitment to improving the quality of life of patients through innovative technologies by extending their benefits to a wider population."

Since its successful listing last year, the Group has actively pursued opportunities to strengthen its business. The incorporation of Eucatech AG's innovative and high-caliber products will bring about technological synergies while allowing the Group to stay ahead of market trends. Therefore, the Group views this acquisition as a strategic move to reinforce its market presence and distribution network .

The Group has demonstrated its unwavering commitment to accelerating business expansion following its listing. Such initiatives include the extension of an exclusive U.S. distribution agreement with Abbott Laboratories' CSI in September to increase U.S. market penetration, the initiation of a clinical trial for Scoreflex TRIO in the PRC in May for product development, and the establishment of its largest R&D and production base in Hangzhou, the PRC, which is expected to commence construction by the end of 2023, to increase R&D and production capacity.

About Eucatech AG

Headquartered in Weil am Rhein, Eucatech AG is a German medical engineering company specializing in the development, manufacture, and sale of minimally invasive cardiovascular and endovascular products. Since 1997, it has been providing innovative product solutions to improve patients' quality of life, including the CE Mark certified EucaLimus Sirolimus Eluting Coronary Stent System, SUPPORT C Paclitaxel Coated Coronary Balloon Catheter, Resistant Peripheral Self-Expandable Stent System and VITUS Paclitaxel Coated PTA Balloon Catheter.

For more information, please visit Eucatech AG's official website: https://eucatech.de/en/home

About OrbusNeich Medical Group Holdings Limited

OrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It also specializes in coronary stent products and is actively expanding into neuro vascular intervention and structural heart disease. As of 30 June 2023, OrbusNeich has more than 210 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.

For more information, please visit the Group's official website: https://orbusneich.com/




Topic: Press release summary
Source: OrbusNeich Medical Group Holdings Limited

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



OrbusNeich Medical Group Holdings Limited
Aug 16, 2024 20:47 HKT/SGT
OrbusNeich Records Net Profit of US$18.8 Million for the First Half of 2024
Apr 24, 2024 18:59 HKT/SGT
OrbusNeich's Joint Venture Kicks Off TricValve Clinical Trial in Mainland China
Mar 7, 2024 17:20 HKT/SGT
OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share
Nov 27, 2023 09:00 HKT/SGT
OrbusNeich Acquires 84% Stake in Indonesian Distributor PT Revass for Approximately US$15 Million
Aug 17, 2023 17:52 HKT/SGT
OrbusNeich FY2023 Interim Net Profit Triples to US$25.2 Million, Total Revenue Increases by 18.2% to US$81.4 Million
May 8, 2023 17:58 HKT/SGT
OrbusNeich Kicks Off Clinical Study of Scoreflex TRIO, Completing China's First PCI Intervention Procedure with High-Pressure, Three-wire Scoring Balloon Dilatation Catheter
Mar 28, 2023 17:28 HKT/SGT
OrbusNeich Plans to Set up Its Largest R&D and Production Base in Fuchun Bay New Town, Hangzhou, the PRC
Mar 8, 2023 18:00 HKT/SGT
OrbusNeich Announces First Annual Results After Listing, Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million
Dec 23, 2022 15:10 HKT/SGT
Shares of Major Global Medical Device Manufacturer OrbusNeich Medical Group Commence Trading on the Main Board of The Stock Exchange of Hong Kong
Dec 13, 2022 10:10 HKT/SGT
Major Global Medical Device Manufacturer OrbusNeich Medical Group Announces Details of Proposed Listing on the Main Board of HKEX
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: